STAT2d
Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...
STAT1d
Study reveals how often medical device makers report safety incidents late to FDA
Most medical devices in the United States come to market with limited clinical data, and device surveillance is viewed as a ...
Fierce Pharma4d
With Eli Lilly flying high, CEO David Ricks collects 10% pay bump to $29.2M
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
Pfizer is latest Big Pharma to overhaul DEI goals after GSK
Pfizer (NYSE:PFE) has made significant updates to its diversity, equity, and inclusion (DEI) webpage, becoming the latest Big ...
Benzinga.com23d
STAT+: How much weight loss is too much? Pharma is pushing the limit with new obesity drugs
In ongoing trials of Eli Lilly’s next-generation obesity drug, several trial participants are running into an issue they never expected: They are losing too much weight. One participant lost 22% ...
BioWorld23d
Recludix Pharma gives update on STAT6 program
Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family involved in the regulation of ... Researchers from Recludix Pharma Inc. have presented the preclinical ...